Global Anti-Obesity Therapeutics Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Anti-Obesity Therapeutics market size was valued at US$ million in 2023. With growing demand in downstream market, the Anti-Obesity Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Anti-Obesity Therapeutics market. Anti-Obesity Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anti-Obesity Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anti-Obesity Therapeutics market.
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Anti-Obesity Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Anti-Obesity Therapeutics market. It may include historical data, market segmentation by Type (e.g., Centrally Acting Anti-obesity Drugs, Peripherally Acting Anti-obesity Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Anti-Obesity Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Anti-Obesity Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Anti-Obesity Therapeutics industry. This include advancements in Anti-Obesity Therapeutics technology, Anti-Obesity Therapeutics new entrants, Anti-Obesity Therapeutics new investment, and other innovations that are shaping the future of Anti-Obesity Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Anti-Obesity Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Anti-Obesity Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Anti-Obesity Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anti-Obesity Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Anti-Obesity Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Anti-Obesity Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anti-Obesity Therapeutics market.
Market Segmentation:
Anti-Obesity Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Anti-Obesity Therapeutics market?
What factors are driving Anti-Obesity Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Obesity Therapeutics market opportunities vary by end market size?
How does Anti-Obesity Therapeutics break out type, application?
According to our LPI (LP Information) latest study, the global Anti-Obesity Therapeutics market size was valued at US$ million in 2023. With growing demand in downstream market, the Anti-Obesity Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Anti-Obesity Therapeutics market. Anti-Obesity Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anti-Obesity Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anti-Obesity Therapeutics market.
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Anti-Obesity Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Anti-Obesity Therapeutics market. It may include historical data, market segmentation by Type (e.g., Centrally Acting Anti-obesity Drugs, Peripherally Acting Anti-obesity Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Anti-Obesity Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Anti-Obesity Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Anti-Obesity Therapeutics industry. This include advancements in Anti-Obesity Therapeutics technology, Anti-Obesity Therapeutics new entrants, Anti-Obesity Therapeutics new investment, and other innovations that are shaping the future of Anti-Obesity Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Anti-Obesity Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Anti-Obesity Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Anti-Obesity Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anti-Obesity Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Anti-Obesity Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Anti-Obesity Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anti-Obesity Therapeutics market.
Market Segmentation:
Anti-Obesity Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Centrally Acting Anti-obesity Drugs
- Peripherally Acting Anti-obesity Drugs
- Hospital Use
- Clinic Use
- Household
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol-Myers Squibb
- Eisai Company
- FlaxoSithKline plc.
- Novo Nordisk
- Alizyme
- BoehringerIngelheim GmbH
- Pfizer
- Takeda Pharmaceutical
- Rhythm Pharmaceuticals
- Shionogi USA
- Vivus
- Zafgen
- Norgine Pharmaceuticals Ltd.
What is the 10-year outlook for the global Anti-Obesity Therapeutics market?
What factors are driving Anti-Obesity Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-Obesity Therapeutics market opportunities vary by end market size?
How does Anti-Obesity Therapeutics break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-Obesity Therapeutics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-Obesity Therapeutics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-Obesity Therapeutics by Country/Region, 2019, 2023 & 2030
2.2 Anti-Obesity Therapeutics Segment by Type
2.2.1 Centrally Acting Anti-obesity Drugs
2.2.2 Peripherally Acting Anti-obesity Drugs
2.3 Anti-Obesity Therapeutics Sales by Type
2.3.1 Global Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-Obesity Therapeutics Sale Price by Type (2019-2024)
2.4 Anti-Obesity Therapeutics Segment by Application
2.4.1 Hospital Use
2.4.2 Clinic Use
2.4.3 Household
2.4.4 Other
2.5 Anti-Obesity Therapeutics Sales by Application
2.5.1 Global Anti-Obesity Therapeutics Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-Obesity Therapeutics Sale Price by Application (2019-2024)
3 GLOBAL ANTI-OBESITY THERAPEUTICS BY COMPANY
3.1 Global Anti-Obesity Therapeutics Breakdown Data by Company
3.1.1 Global Anti-Obesity Therapeutics Annual Sales by Company (2019-2024)
3.1.2 Global Anti-Obesity Therapeutics Sales Market Share by Company (2019-2024)
3.2 Global Anti-Obesity Therapeutics Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-Obesity Therapeutics Revenue by Company (2019-2024)
3.2.2 Global Anti-Obesity Therapeutics Revenue Market Share by Company (2019-2024)
3.3 Global Anti-Obesity Therapeutics Sale Price by Company
3.4 Key Manufacturers Anti-Obesity Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-Obesity Therapeutics Product Location Distribution
3.4.2 Players Anti-Obesity Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-OBESITY THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Anti-Obesity Therapeutics Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-Obesity Therapeutics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-Obesity Therapeutics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-Obesity Therapeutics Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-Obesity Therapeutics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-Obesity Therapeutics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-Obesity Therapeutics Sales Growth
4.4 APAC Anti-Obesity Therapeutics Sales Growth
4.5 Europe Anti-Obesity Therapeutics Sales Growth
4.6 Middle East & Africa Anti-Obesity Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Anti-Obesity Therapeutics Sales by Country
5.1.1 Americas Anti-Obesity Therapeutics Sales by Country (2019-2024)
5.1.2 Americas Anti-Obesity Therapeutics Revenue by Country (2019-2024)
5.2 Americas Anti-Obesity Therapeutics Sales by Type
5.3 Americas Anti-Obesity Therapeutics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-Obesity Therapeutics Sales by Region
6.1.1 APAC Anti-Obesity Therapeutics Sales by Region (2019-2024)
6.1.2 APAC Anti-Obesity Therapeutics Revenue by Region (2019-2024)
6.2 APAC Anti-Obesity Therapeutics Sales by Type
6.3 APAC Anti-Obesity Therapeutics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-Obesity Therapeutics by Country
7.1.1 Europe Anti-Obesity Therapeutics Sales by Country (2019-2024)
7.1.2 Europe Anti-Obesity Therapeutics Revenue by Country (2019-2024)
7.2 Europe Anti-Obesity Therapeutics Sales by Type
7.3 Europe Anti-Obesity Therapeutics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-Obesity Therapeutics by Country
8.1.1 Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-Obesity Therapeutics Sales by Type
8.3 Middle East & Africa Anti-Obesity Therapeutics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-Obesity Therapeutics
10.3 Manufacturing Process Analysis of Anti-Obesity Therapeutics
10.4 Industry Chain Structure of Anti-Obesity Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-Obesity Therapeutics Distributors
11.3 Anti-Obesity Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ANTI-OBESITY THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Anti-Obesity Therapeutics Market Size Forecast by Region
12.1.1 Global Anti-Obesity Therapeutics Forecast by Region (2025-2030)
12.1.2 Global Anti-Obesity Therapeutics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-Obesity Therapeutics Forecast by Type
12.7 Global Anti-Obesity Therapeutics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Information
13.1.2 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolios and Specifications
13.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol-Myers Squibb Main Business Overview
13.1.5 Bristol-Myers Squibb Latest Developments
13.2 Eisai Company
13.2.1 Eisai Company Company Information
13.2.2 Eisai Company Anti-Obesity Therapeutics Product Portfolios and Specifications
13.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Eisai Company Main Business Overview
13.2.5 Eisai Company Latest Developments
13.3 FlaxoSithKline plc.
13.3.1 FlaxoSithKline plc. Company Information
13.3.2 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolios and Specifications
13.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 FlaxoSithKline plc. Main Business Overview
13.3.5 FlaxoSithKline plc. Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Anti-Obesity Therapeutics Product Portfolios and Specifications
13.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Alizyme
13.5.1 Alizyme Company Information
13.5.2 Alizyme Anti-Obesity Therapeutics Product Portfolios and Specifications
13.5.3 Alizyme Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Alizyme Main Business Overview
13.5.5 Alizyme Latest Developments
13.6 BoehringerIngelheim GmbH
13.6.1 BoehringerIngelheim GmbH Company Information
13.6.2 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolios and Specifications
13.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 BoehringerIngelheim GmbH Main Business Overview
13.6.5 BoehringerIngelheim GmbH Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Anti-Obesity Therapeutics Product Portfolios and Specifications
13.7.3 Pfizer Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Takeda Pharmaceutical
13.8.1 Takeda Pharmaceutical Company Information
13.8.2 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Takeda Pharmaceutical Main Business Overview
13.8.5 Takeda Pharmaceutical Latest Developments
13.9 Rhythm Pharmaceuticals
13.9.1 Rhythm Pharmaceuticals Company Information
13.9.2 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolios and Specifications
13.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Rhythm Pharmaceuticals Main Business Overview
13.9.5 Rhythm Pharmaceuticals Latest Developments
13.10 Shionogi USA
13.10.1 Shionogi USA Company Information
13.10.2 Shionogi USA Anti-Obesity Therapeutics Product Portfolios and Specifications
13.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shionogi USA Main Business Overview
13.10.5 Shionogi USA Latest Developments
13.11 Vivus
13.11.1 Vivus Company Information
13.11.2 Vivus Anti-Obesity Therapeutics Product Portfolios and Specifications
13.11.3 Vivus Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Vivus Main Business Overview
13.11.5 Vivus Latest Developments
13.12 Zafgen
13.12.1 Zafgen Company Information
13.12.2 Zafgen Anti-Obesity Therapeutics Product Portfolios and Specifications
13.12.3 Zafgen Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zafgen Main Business Overview
13.12.5 Zafgen Latest Developments
13.13 Norgine Pharmaceuticals Ltd.
13.13.1 Norgine Pharmaceuticals Ltd. Company Information
13.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolios and Specifications
13.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Norgine Pharmaceuticals Ltd. Main Business Overview
13.13.5 Norgine Pharmaceuticals Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-Obesity Therapeutics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-Obesity Therapeutics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-Obesity Therapeutics by Country/Region, 2019, 2023 & 2030
2.2 Anti-Obesity Therapeutics Segment by Type
2.2.1 Centrally Acting Anti-obesity Drugs
2.2.2 Peripherally Acting Anti-obesity Drugs
2.3 Anti-Obesity Therapeutics Sales by Type
2.3.1 Global Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-Obesity Therapeutics Sale Price by Type (2019-2024)
2.4 Anti-Obesity Therapeutics Segment by Application
2.4.1 Hospital Use
2.4.2 Clinic Use
2.4.3 Household
2.4.4 Other
2.5 Anti-Obesity Therapeutics Sales by Application
2.5.1 Global Anti-Obesity Therapeutics Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-Obesity Therapeutics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-Obesity Therapeutics Sale Price by Application (2019-2024)
3 GLOBAL ANTI-OBESITY THERAPEUTICS BY COMPANY
3.1 Global Anti-Obesity Therapeutics Breakdown Data by Company
3.1.1 Global Anti-Obesity Therapeutics Annual Sales by Company (2019-2024)
3.1.2 Global Anti-Obesity Therapeutics Sales Market Share by Company (2019-2024)
3.2 Global Anti-Obesity Therapeutics Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-Obesity Therapeutics Revenue by Company (2019-2024)
3.2.2 Global Anti-Obesity Therapeutics Revenue Market Share by Company (2019-2024)
3.3 Global Anti-Obesity Therapeutics Sale Price by Company
3.4 Key Manufacturers Anti-Obesity Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-Obesity Therapeutics Product Location Distribution
3.4.2 Players Anti-Obesity Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTI-OBESITY THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Anti-Obesity Therapeutics Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-Obesity Therapeutics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-Obesity Therapeutics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-Obesity Therapeutics Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-Obesity Therapeutics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-Obesity Therapeutics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-Obesity Therapeutics Sales Growth
4.4 APAC Anti-Obesity Therapeutics Sales Growth
4.5 Europe Anti-Obesity Therapeutics Sales Growth
4.6 Middle East & Africa Anti-Obesity Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Anti-Obesity Therapeutics Sales by Country
5.1.1 Americas Anti-Obesity Therapeutics Sales by Country (2019-2024)
5.1.2 Americas Anti-Obesity Therapeutics Revenue by Country (2019-2024)
5.2 Americas Anti-Obesity Therapeutics Sales by Type
5.3 Americas Anti-Obesity Therapeutics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-Obesity Therapeutics Sales by Region
6.1.1 APAC Anti-Obesity Therapeutics Sales by Region (2019-2024)
6.1.2 APAC Anti-Obesity Therapeutics Revenue by Region (2019-2024)
6.2 APAC Anti-Obesity Therapeutics Sales by Type
6.3 APAC Anti-Obesity Therapeutics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-Obesity Therapeutics by Country
7.1.1 Europe Anti-Obesity Therapeutics Sales by Country (2019-2024)
7.1.2 Europe Anti-Obesity Therapeutics Revenue by Country (2019-2024)
7.2 Europe Anti-Obesity Therapeutics Sales by Type
7.3 Europe Anti-Obesity Therapeutics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-Obesity Therapeutics by Country
8.1.1 Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-Obesity Therapeutics Sales by Type
8.3 Middle East & Africa Anti-Obesity Therapeutics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-Obesity Therapeutics
10.3 Manufacturing Process Analysis of Anti-Obesity Therapeutics
10.4 Industry Chain Structure of Anti-Obesity Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-Obesity Therapeutics Distributors
11.3 Anti-Obesity Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ANTI-OBESITY THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Anti-Obesity Therapeutics Market Size Forecast by Region
12.1.1 Global Anti-Obesity Therapeutics Forecast by Region (2025-2030)
12.1.2 Global Anti-Obesity Therapeutics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Anti-Obesity Therapeutics Forecast by Type
12.7 Global Anti-Obesity Therapeutics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Information
13.1.2 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolios and Specifications
13.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol-Myers Squibb Main Business Overview
13.1.5 Bristol-Myers Squibb Latest Developments
13.2 Eisai Company
13.2.1 Eisai Company Company Information
13.2.2 Eisai Company Anti-Obesity Therapeutics Product Portfolios and Specifications
13.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Eisai Company Main Business Overview
13.2.5 Eisai Company Latest Developments
13.3 FlaxoSithKline plc.
13.3.1 FlaxoSithKline plc. Company Information
13.3.2 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolios and Specifications
13.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 FlaxoSithKline plc. Main Business Overview
13.3.5 FlaxoSithKline plc. Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Anti-Obesity Therapeutics Product Portfolios and Specifications
13.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Alizyme
13.5.1 Alizyme Company Information
13.5.2 Alizyme Anti-Obesity Therapeutics Product Portfolios and Specifications
13.5.3 Alizyme Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Alizyme Main Business Overview
13.5.5 Alizyme Latest Developments
13.6 BoehringerIngelheim GmbH
13.6.1 BoehringerIngelheim GmbH Company Information
13.6.2 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolios and Specifications
13.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 BoehringerIngelheim GmbH Main Business Overview
13.6.5 BoehringerIngelheim GmbH Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Anti-Obesity Therapeutics Product Portfolios and Specifications
13.7.3 Pfizer Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Takeda Pharmaceutical
13.8.1 Takeda Pharmaceutical Company Information
13.8.2 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Takeda Pharmaceutical Main Business Overview
13.8.5 Takeda Pharmaceutical Latest Developments
13.9 Rhythm Pharmaceuticals
13.9.1 Rhythm Pharmaceuticals Company Information
13.9.2 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolios and Specifications
13.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Rhythm Pharmaceuticals Main Business Overview
13.9.5 Rhythm Pharmaceuticals Latest Developments
13.10 Shionogi USA
13.10.1 Shionogi USA Company Information
13.10.2 Shionogi USA Anti-Obesity Therapeutics Product Portfolios and Specifications
13.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shionogi USA Main Business Overview
13.10.5 Shionogi USA Latest Developments
13.11 Vivus
13.11.1 Vivus Company Information
13.11.2 Vivus Anti-Obesity Therapeutics Product Portfolios and Specifications
13.11.3 Vivus Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Vivus Main Business Overview
13.11.5 Vivus Latest Developments
13.12 Zafgen
13.12.1 Zafgen Company Information
13.12.2 Zafgen Anti-Obesity Therapeutics Product Portfolios and Specifications
13.12.3 Zafgen Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zafgen Main Business Overview
13.12.5 Zafgen Latest Developments
13.13 Norgine Pharmaceuticals Ltd.
13.13.1 Norgine Pharmaceuticals Ltd. Company Information
13.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolios and Specifications
13.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Norgine Pharmaceuticals Ltd. Main Business Overview
13.13.5 Norgine Pharmaceuticals Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-Obesity Therapeutics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-Obesity Therapeutics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Centrally Acting Anti-obesity Drugs
Table 4. Major Players of Peripherally Acting Anti-obesity Drugs
Table 5. Global Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 6. Global Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Table 7. Global Anti-Obesity Therapeutics Revenue by Type (2019-2024) & ($ million)
Table 8. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2019-2024)
Table 9. Global Anti-Obesity Therapeutics Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 11. Global Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Table 12. Global Anti-Obesity Therapeutics Revenue by Application (2019-2024)
Table 13. Global Anti-Obesity Therapeutics Revenue Market Share by Application (2019-2024)
Table 14. Global Anti-Obesity Therapeutics Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Anti-Obesity Therapeutics Sales by Company (2019-2024) & (K Units)
Table 16. Global Anti-Obesity Therapeutics Sales Market Share by Company (2019-2024)
Table 17. Global Anti-Obesity Therapeutics Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Anti-Obesity Therapeutics Revenue Market Share by Company (2019-2024)
Table 19. Global Anti-Obesity Therapeutics Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Anti-Obesity Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Anti-Obesity Therapeutics Products Offered
Table 22. Anti-Obesity Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Anti-Obesity Therapeutics Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Anti-Obesity Therapeutics Sales Market Share Geographic Region (2019-2024)
Table 27. Global Anti-Obesity Therapeutics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Anti-Obesity Therapeutics Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Anti-Obesity Therapeutics Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Anti-Obesity Therapeutics Sales Market Share by Country/Region (2019-2024)
Table 31. Global Anti-Obesity Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Anti-Obesity Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 34. Americas Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 35. Americas Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 37. Americas Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 38. Americas Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 39. APAC Anti-Obesity Therapeutics Sales by Region (2019-2024) & (K Units)
Table 40. APAC Anti-Obesity Therapeutics Sales Market Share by Region (2019-2024)
Table 41. APAC Anti-Obesity Therapeutics Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Anti-Obesity Therapeutics Revenue Market Share by Region (2019-2024)
Table 43. APAC Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 44. APAC Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 45. Europe Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 46. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 47. Europe Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 49. Europe Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 50. Europe Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Anti-Obesity Therapeutics
Table 58. Key Market Challenges & Risks of Anti-Obesity Therapeutics
Table 59. Key Industry Trends of Anti-Obesity Therapeutics
Table 60. Anti-Obesity Therapeutics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Anti-Obesity Therapeutics Distributors List
Table 63. Anti-Obesity Therapeutics Customer List
Table 64. Global Anti-Obesity Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Anti-Obesity Therapeutics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Anti-Obesity Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Anti-Obesity Therapeutics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Anti-Obesity Therapeutics Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Anti-Obesity Therapeutics Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Anti-Obesity Therapeutics Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Anti-Obesity Therapeutics Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Bristol-Myers Squibb Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 79. Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 80. Bristol-Myers Squibb Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Bristol-Myers Squibb Main Business
Table 82. Bristol-Myers Squibb Latest Developments
Table 83. Eisai Company Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 84. Eisai Company Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 85. Eisai Company Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Eisai Company Main Business
Table 87. Eisai Company Latest Developments
Table 88. FlaxoSithKline plc. Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 90. FlaxoSithKline plc. Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. FlaxoSithKline plc. Main Business
Table 92. FlaxoSithKline plc. Latest Developments
Table 93. Novo Nordisk Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 95. Novo Nordisk Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. Alizyme Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. Alizyme Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 100. Alizyme Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Alizyme Main Business
Table 102. Alizyme Latest Developments
Table 103. BoehringerIngelheim GmbH Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 104. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 105. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. BoehringerIngelheim GmbH Main Business
Table 107. BoehringerIngelheim GmbH Latest Developments
Table 108. Pfizer Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 110. Pfizer Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Takeda Pharmaceutical Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 114. Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 115. Takeda Pharmaceutical Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Takeda Pharmaceutical Main Business
Table 117. Takeda Pharmaceutical Latest Developments
Table 118. Rhythm Pharmaceuticals Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 119. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 120. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Rhythm Pharmaceuticals Main Business
Table 122. Rhythm Pharmaceuticals Latest Developments
Table 123. Shionogi USA Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 124. Shionogi USA Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 125. Shionogi USA Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. Shionogi USA Main Business
Table 127. Shionogi USA Latest Developments
Table 128. Vivus Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 129. Vivus Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 130. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 131. Vivus Main Business
Table 132. Vivus Latest Developments
Table 133. Zafgen Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 134. Zafgen Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 135. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 136. Zafgen Main Business
Table 137. Zafgen Latest Developments
Table 138. Norgine Pharmaceuticals Ltd. Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 139. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 140. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 141. Norgine Pharmaceuticals Ltd. Main Business
Table 142. Norgine Pharmaceuticals Ltd. Latest Developments
Table 1. Anti-Obesity Therapeutics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-Obesity Therapeutics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Centrally Acting Anti-obesity Drugs
Table 4. Major Players of Peripherally Acting Anti-obesity Drugs
Table 5. Global Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 6. Global Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Table 7. Global Anti-Obesity Therapeutics Revenue by Type (2019-2024) & ($ million)
Table 8. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2019-2024)
Table 9. Global Anti-Obesity Therapeutics Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 11. Global Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Table 12. Global Anti-Obesity Therapeutics Revenue by Application (2019-2024)
Table 13. Global Anti-Obesity Therapeutics Revenue Market Share by Application (2019-2024)
Table 14. Global Anti-Obesity Therapeutics Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Anti-Obesity Therapeutics Sales by Company (2019-2024) & (K Units)
Table 16. Global Anti-Obesity Therapeutics Sales Market Share by Company (2019-2024)
Table 17. Global Anti-Obesity Therapeutics Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Anti-Obesity Therapeutics Revenue Market Share by Company (2019-2024)
Table 19. Global Anti-Obesity Therapeutics Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Anti-Obesity Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Anti-Obesity Therapeutics Products Offered
Table 22. Anti-Obesity Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Anti-Obesity Therapeutics Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Anti-Obesity Therapeutics Sales Market Share Geographic Region (2019-2024)
Table 27. Global Anti-Obesity Therapeutics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Anti-Obesity Therapeutics Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Anti-Obesity Therapeutics Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Anti-Obesity Therapeutics Sales Market Share by Country/Region (2019-2024)
Table 31. Global Anti-Obesity Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Anti-Obesity Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 34. Americas Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 35. Americas Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 37. Americas Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 38. Americas Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 39. APAC Anti-Obesity Therapeutics Sales by Region (2019-2024) & (K Units)
Table 40. APAC Anti-Obesity Therapeutics Sales Market Share by Region (2019-2024)
Table 41. APAC Anti-Obesity Therapeutics Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Anti-Obesity Therapeutics Revenue Market Share by Region (2019-2024)
Table 43. APAC Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 44. APAC Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 45. Europe Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 46. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 47. Europe Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 49. Europe Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 50. Europe Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Anti-Obesity Therapeutics Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Anti-Obesity Therapeutics Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Anti-Obesity Therapeutics
Table 58. Key Market Challenges & Risks of Anti-Obesity Therapeutics
Table 59. Key Industry Trends of Anti-Obesity Therapeutics
Table 60. Anti-Obesity Therapeutics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Anti-Obesity Therapeutics Distributors List
Table 63. Anti-Obesity Therapeutics Customer List
Table 64. Global Anti-Obesity Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Anti-Obesity Therapeutics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Anti-Obesity Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Anti-Obesity Therapeutics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Anti-Obesity Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Anti-Obesity Therapeutics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Anti-Obesity Therapeutics Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Anti-Obesity Therapeutics Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Anti-Obesity Therapeutics Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Anti-Obesity Therapeutics Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Bristol-Myers Squibb Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 79. Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 80. Bristol-Myers Squibb Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. Bristol-Myers Squibb Main Business
Table 82. Bristol-Myers Squibb Latest Developments
Table 83. Eisai Company Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 84. Eisai Company Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 85. Eisai Company Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Eisai Company Main Business
Table 87. Eisai Company Latest Developments
Table 88. FlaxoSithKline plc. Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 90. FlaxoSithKline plc. Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. FlaxoSithKline plc. Main Business
Table 92. FlaxoSithKline plc. Latest Developments
Table 93. Novo Nordisk Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 95. Novo Nordisk Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. Alizyme Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. Alizyme Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 100. Alizyme Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. Alizyme Main Business
Table 102. Alizyme Latest Developments
Table 103. BoehringerIngelheim GmbH Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 104. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 105. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. BoehringerIngelheim GmbH Main Business
Table 107. BoehringerIngelheim GmbH Latest Developments
Table 108. Pfizer Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 110. Pfizer Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Takeda Pharmaceutical Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 114. Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 115. Takeda Pharmaceutical Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Takeda Pharmaceutical Main Business
Table 117. Takeda Pharmaceutical Latest Developments
Table 118. Rhythm Pharmaceuticals Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 119. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 120. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Rhythm Pharmaceuticals Main Business
Table 122. Rhythm Pharmaceuticals Latest Developments
Table 123. Shionogi USA Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 124. Shionogi USA Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 125. Shionogi USA Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. Shionogi USA Main Business
Table 127. Shionogi USA Latest Developments
Table 128. Vivus Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 129. Vivus Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 130. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 131. Vivus Main Business
Table 132. Vivus Latest Developments
Table 133. Zafgen Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 134. Zafgen Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 135. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 136. Zafgen Main Business
Table 137. Zafgen Latest Developments
Table 138. Norgine Pharmaceuticals Ltd. Basic Information, Anti-Obesity Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 139. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolios and Specifications
Table 140. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 141. Norgine Pharmaceuticals Ltd. Main Business
Table 142. Norgine Pharmaceuticals Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-Obesity Therapeutics
Figure 2. Anti-Obesity Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-Obesity Therapeutics Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-Obesity Therapeutics Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-Obesity Therapeutics Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Centrally Acting Anti-obesity Drugs
Figure 10. Product Picture of Peripherally Acting Anti-obesity Drugs
Figure 11. Global Anti-Obesity Therapeutics Sales Market Share by Type in 2023
Figure 12. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2019-2024)
Figure 13. Anti-Obesity Therapeutics Consumed in Hospital Use
Figure 14. Global Anti-Obesity Therapeutics Market: Hospital Use (2019-2024) & (K Units)
Figure 15. Anti-Obesity Therapeutics Consumed in Clinic Use
Figure 16. Global Anti-Obesity Therapeutics Market: Clinic Use (2019-2024) & (K Units)
Figure 17. Anti-Obesity Therapeutics Consumed in Household
Figure 18. Global Anti-Obesity Therapeutics Market: Household (2019-2024) & (K Units)
Figure 19. Anti-Obesity Therapeutics Consumed in Other
Figure 20. Global Anti-Obesity Therapeutics Market: Other (2019-2024) & (K Units)
Figure 21. Global Anti-Obesity Therapeutics Sales Market Share by Application (2023)
Figure 22. Global Anti-Obesity Therapeutics Revenue Market Share by Application in 2023
Figure 23. Anti-Obesity Therapeutics Sales Market by Company in 2023 (K Units)
Figure 24. Global Anti-Obesity Therapeutics Sales Market Share by Company in 2023
Figure 25. Anti-Obesity Therapeutics Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Anti-Obesity Therapeutics Revenue Market Share by Company in 2023
Figure 27. Global Anti-Obesity Therapeutics Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Anti-Obesity Therapeutics Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 30. Americas Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 31. APAC Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 32. APAC Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 33. Europe Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 34. Europe Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 37. Americas Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 38. Americas Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 39. Americas Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 40. Americas Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 41. United States Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Anti-Obesity Therapeutics Sales Market Share by Region in 2023
Figure 46. APAC Anti-Obesity Therapeutics Revenue Market Share by Regions in 2023
Figure 47. APAC Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 48. APAC Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 49. China Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 57. Europe Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 58. Europe Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 59. Europe Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 60. Germany Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 69. Egypt Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Anti-Obesity Therapeutics in 2023
Figure 75. Manufacturing Process Analysis of Anti-Obesity Therapeutics
Figure 76. Industry Chain Structure of Anti-Obesity Therapeutics
Figure 77. Channels of Distribution
Figure 78. Global Anti-Obesity Therapeutics Sales Market Forecast by Region (2025-2030)
Figure 79. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Anti-Obesity Therapeutics
Figure 2. Anti-Obesity Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-Obesity Therapeutics Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Anti-Obesity Therapeutics Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Anti-Obesity Therapeutics Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Centrally Acting Anti-obesity Drugs
Figure 10. Product Picture of Peripherally Acting Anti-obesity Drugs
Figure 11. Global Anti-Obesity Therapeutics Sales Market Share by Type in 2023
Figure 12. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2019-2024)
Figure 13. Anti-Obesity Therapeutics Consumed in Hospital Use
Figure 14. Global Anti-Obesity Therapeutics Market: Hospital Use (2019-2024) & (K Units)
Figure 15. Anti-Obesity Therapeutics Consumed in Clinic Use
Figure 16. Global Anti-Obesity Therapeutics Market: Clinic Use (2019-2024) & (K Units)
Figure 17. Anti-Obesity Therapeutics Consumed in Household
Figure 18. Global Anti-Obesity Therapeutics Market: Household (2019-2024) & (K Units)
Figure 19. Anti-Obesity Therapeutics Consumed in Other
Figure 20. Global Anti-Obesity Therapeutics Market: Other (2019-2024) & (K Units)
Figure 21. Global Anti-Obesity Therapeutics Sales Market Share by Application (2023)
Figure 22. Global Anti-Obesity Therapeutics Revenue Market Share by Application in 2023
Figure 23. Anti-Obesity Therapeutics Sales Market by Company in 2023 (K Units)
Figure 24. Global Anti-Obesity Therapeutics Sales Market Share by Company in 2023
Figure 25. Anti-Obesity Therapeutics Revenue Market by Company in 2023 ($ Million)
Figure 26. Global Anti-Obesity Therapeutics Revenue Market Share by Company in 2023
Figure 27. Global Anti-Obesity Therapeutics Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Anti-Obesity Therapeutics Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 30. Americas Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 31. APAC Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 32. APAC Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 33. Europe Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 34. Europe Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 35. Middle East & Africa Anti-Obesity Therapeutics Sales 2019-2024 (K Units)
Figure 36. Middle East & Africa Anti-Obesity Therapeutics Revenue 2019-2024 ($ Millions)
Figure 37. Americas Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 38. Americas Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 39. Americas Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 40. Americas Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 41. United States Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 42. Canada Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 43. Mexico Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 44. Brazil Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 45. APAC Anti-Obesity Therapeutics Sales Market Share by Region in 2023
Figure 46. APAC Anti-Obesity Therapeutics Revenue Market Share by Regions in 2023
Figure 47. APAC Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 48. APAC Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 49. China Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 50. Japan Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 51. South Korea Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 52. Southeast Asia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 53. India Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 54. Australia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 55. China Taiwan Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 56. Europe Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 57. Europe Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 58. Europe Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 59. Europe Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 60. Germany Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 61. France Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 62. UK Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 63. Italy Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 64. Russia Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 65. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Country in 2023
Figure 66. Middle East & Africa Anti-Obesity Therapeutics Revenue Market Share by Country in 2023
Figure 67. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Type (2019-2024)
Figure 68. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Application (2019-2024)
Figure 69. Egypt Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 70. South Africa Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 71. Israel Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 72. Turkey Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 73. GCC Country Anti-Obesity Therapeutics Revenue Growth 2019-2024 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Anti-Obesity Therapeutics in 2023
Figure 75. Manufacturing Process Analysis of Anti-Obesity Therapeutics
Figure 76. Industry Chain Structure of Anti-Obesity Therapeutics
Figure 77. Channels of Distribution
Figure 78. Global Anti-Obesity Therapeutics Sales Market Forecast by Region (2025-2030)
Figure 79. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Region (2025-2030)
Figure 80. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 81. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Type (2025-2030)
Figure 82. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Application (2025-2030)
Figure 83. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Pediatric Thermometer Market Growth 2024-2030
US$ 3,660.00
November 2024
108 pages
Global Portable Emergency Eyewash Station Market Growth 2024-2030
US$ 3,660.00
March 2024
95 pages
Global Portable Automatic Kerato Refractometer Market Growth 2024-2030
US$ 3,660.00
March 2024
101 pages
Global Animal Drugs Market Growth 2023-2029
US$ 3,660.00
February 2023
98 pages
Global PEGylated Protein Therapeutics Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
92 pages
